[Federal Register Volume 79, Number 165 (Tuesday, August 26, 2014)]
[Notices]
[Page 50950]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-20198]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Manufacturer of Controlled Substances Registration: Patheon 
Pharmaceuticals, Inc.

ACTION: Notice of registration.

-----------------------------------------------------------------------

SUMMARY: Patheon Pharmaceuticals, Inc., applied to be registered as a 
manufacturer of a certain basic class of controlled substance. The DEA 
grants Patheon Pharmaceuticals, Inc., registration as a manufacturer of 
the controlled substance.

SUPPLEMENTARY INFORMATION: By notice dated April 21, 2014, and 
published in the Federal Register on April 28, 2014, 79 FR 23373, 
Patheon Pharmaceuticals, Inc., 2110 E. Galbraith Road, Cincinnati, Ohio 
45237, applied to be registered as a manufacturer of a certain basic 
class of non-narcotic controlled substance. No comments or objections 
have been received.
    The Drug Enforcement Administration (DEA) has considered the 
factors in 21 U.S.C. 823(a) and determined that the registration of 
Patheon Pharmaceuticals, Inc., to manufacture the basic class of this 
controlled substance is consistent with the public interest and with 
United States obligations under international treaties, conventions, or 
protocols in effect on May 1, 1971. The DEA investigated the company's 
maintenance of effective controls against diversion by inspecting and 
testing the company's physical security systems, verifying the 
company's compliance with state and local laws, and reviewing the 
company's background and history.
    Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 
CFR 1301.33, the above-named company is granted registration as a bulk 
manufacturer of Gamma Hydroxybutyric Acid (2010), a basic class of 
controlled substance listed in schedule I.
    The company plans to manufacture the listed controlled substance 
for distribution to its customers.

    Dated: August 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-20198 Filed 8-25-14; 8:45 am]
BILLING CODE 4410-09-P